Wall Street analysts expect that Merus NV (NASDAQ:MRUS) will post earnings of ($0.46) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Merus’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.41). Merus reported earnings per share of ($0.55) during the same quarter last year, which would indicate a positive year-over-year growth rate of 16.4%. The business is expected to issue its next quarterly earnings results on Thursday, December 26th.
According to Zacks, analysts expect that Merus will report full year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.76) to ($1.69). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.45) per share, with EPS estimates ranging from ($2.07) to ($0.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Merus.
Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Monday, August 19th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.03). Merus had a negative net margin of 104.10% and a negative return on equity of 41.68%. The firm had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $8.62 million.
A number of hedge funds have recently modified their holdings of MRUS. JPMorgan Chase & Co. boosted its holdings in Merus by 63.5% in the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 3,389 shares during the last quarter. Artal Group S.A. boosted its holdings in Merus by 16.7% in the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock worth $5,128,000 after purchasing an additional 50,000 shares during the last quarter. Athanor Capital LP purchased a new stake in Merus in the second quarter worth approximately $334,000. Finally, Morgan Stanley boosted its holdings in Merus by 3.1% in the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock worth $1,359,000 after purchasing an additional 2,788 shares during the last quarter. Institutional investors own 52.00% of the company’s stock.
Shares of NASDAQ:MRUS traded up $0.29 during trading on Wednesday, reaching $16.70. 245 shares of the stock traded hands, compared to its average volume of 48,522. The stock has a 50-day moving average of $17.18 and a two-hundred day moving average of $15.40. Merus has a 52-week low of $11.00 and a 52-week high of $20.95. The stock has a market cap of $376.29 million, a P/E ratio of -9.01 and a beta of 0.24.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More: What is a bull market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.